Purchase this article with an account.
Younghoon Lee, Seok Hyeon Song, Byung Yi Ko; Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5003.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the effect of 0.1% bromfenac sodium hydrate ophthalmic solution for prevention of macular edema after cataract surgery in patients with diabetes.
We performed a retrospective analysis of 71 patients with diabetes who underwent cataract surgery and followed up more than 6 months. 38 patients (51 eyes) instilled 0.1% bromfenac solution(bromfenac group) and 33 patients (39 eyes) did not(control group).
There were no significant defference between the group. Best corrected visual acuity (BCVA) was significantly improved at all visit time in both groups than before surgery, and there was no significant difference between the two groups. At 1 month postoperatively, the central macular thickness (CMT) of the control group (314.15 ± 76.11μm) was significantly thicker than the bromfenac group (264 ± 31μm)(p <0.001), but no significant difference was found at 4 and 6 months. The mean change of CMT was significantly less in bromfenac group at 1 (-1.44 ± 11.72μm vs 47.19 ± 70.24μm, p <0.001) and 4 months (10.44 ± 22.48μm vs 31.69 ± 48.04μm, p=0.016), but there was no statistically significant difference between the two groups at 6 months after surgery (3.7 ± 24.13μm for the bromfenac group vs 16.65 ± 38.59μm for the control group, p=0.053).
0.1% Bromfenac sodium hydrate ophthalmic solution showed good efficacy for preventing cystoid macular edema after cataract surgery in patients with diabetes.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only